RLS Global AB (publ) announced that the outcome of the completed clinical study ChloSolv01 is published on June 14, 2021 in t the Journal of Wound Care Vol 30, No 6, June 2021. Data from this clinical study show that a treatment regimen based on ChloraSolv could represent a valuable treatment option for patients suffering from hard-to-heal wounds. The wounds that were treated in the ChloraSolv01 clinical study were hard-to-heal, lower extremity ulcers which had more than 50% coverage of devitalized tissue. Using ChloraSolv once a week for 5 weeks resulted in a 73% reduction of the devitalized tissue and the reduction of wound size during the study period shows that ChloraSolv does not negatively affect the natural healing process. The treatment was generally well tolerated, and patients reported a low pain score during the treatments. It is also shown that the treatment was perceived as positive and easy to handle both from the perspective of care recipients and caregivers.